FOI - Information request on Nobivac Lepto 4 vaccine
Published 19 November 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/vmd-foieir-requests-august-2025/foi-information-request-on-nobivac-lepto-4-vaccine
ATI1102 Request
In the interest of transparency please send me the results of laboratory and field studies on Nobivac Lepto 4 vaccine (MSD/Merck Animal Health).
Our reply
The proprietary data from trials carried out during the development of Nobivac L4 are commercially sensitive information. We judge that the Section 43 exemption of the Freedom of Information Act, information that constitutes a trade secret or would, or would be likely to, prejudice commercial interests, applies in this case. After careful consideration we conclude that the public interest in withholding the information strongly outweighs that for disclosure.